Ultragenyx Pharmaceutical (RARE) News Today $44.75 -2.89 (-6.07%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Strong Buy Rating for Ultragenyx Pharmaceutical: Promising Phase 3 Prospects and Market ConfidenceNovember 13, 2024 | markets.businessinsider.comFY2024 EPS Estimates for RARE Lifted by Cantor FitzgeraldNovember 13, 2024 | americanbankingnews.comUltragenyx: Ready For More Growth After Q3 Earnings BeatNovember 12, 2024 | seekingalpha.comUltragenyx Pharmaceutical's (RARE) "Buy" Rating Reaffirmed at Canaccord Genuity GroupCanaccord Genuity Group reissued a "buy" rating and issued a $121.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday.November 12, 2024 | marketbeat.comFY2024 EPS Estimates for RARE Raised by Cantor FitzgeraldUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday, November 6th. Cantor Fitzgerald analyst K. Kluska now foNovember 11, 2024 | marketbeat.comFY2024 Earnings Forecast for RARE Issued By Leerink PartnrsNovember 10, 2024 | americanbankingnews.comUltragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science SummitNovember 9, 2024 | uk.finance.yahoo.comUltragenyx posts trial data backing Phase 3 design for Angelman syndrome therapyNovember 9, 2024 | msn.comUltragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science SummitNovember 9, 2024 | globenewswire.comWhat is HC Wainwright's Estimate for RARE FY2024 Earnings?Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Research analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a research note issued on Wednesday, November 6th. HC Wainwright analyst E. Arce now expects that the biopharmaceNovember 8, 2024 | marketbeat.comLeerink Partnrs Has Pessimistic View of RARE FY2024 EarningsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2024 earnings estimates for Ultragenyx Pharmaceutical in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharNovember 8, 2024 | marketbeat.comWhat is Wedbush's Forecast for RARE FY2024 Earnings?Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Investment analysts at Wedbush dropped their FY2024 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Wednesday, November 6th. Wedbush analyst L. Chico now expects that the biopharmaceutical company willNovember 8, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for RARE Q1 Earnings?November 8, 2024 | americanbankingnews.comEquities Analysts Set Expectations for RARE Q1 EarningsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday, November 6th. HC Wainwright analyst E. Arce forecasts thatNovember 7, 2024 | marketbeat.comEvercore ISI Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)November 7, 2024 | markets.businessinsider.comBank of America Securities Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)November 6, 2024 | markets.businessinsider.comUltragenyx Pharmaceutical’s Promising Growth and Strategic Advances Justify Buy RatingNovember 6, 2024 | markets.businessinsider.comUltragenyx Reports Strong Q3 Growth and MilestonesNovember 6, 2024 | markets.businessinsider.comUltragenyx Pharmaceutical: Promising Clinical Pipeline and Strong Growth Prospects Justify Buy RatingNovember 6, 2024 | markets.businessinsider.comUltragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ...November 6, 2024 | finance.yahoo.comEvaluating Ultragenyx Pharmaceutical: Insights From 7 Financial AnalystsNovember 6, 2024 | benzinga.comUltragenyx Pharmaceutical (NASDAQ:RARE) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday.November 6, 2024 | marketbeat.comHC Wainwright Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $95.00HC Wainwright lifted their target price on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a "buy" rating in a research report on Wednesday.November 6, 2024 | marketbeat.comUltragenyx: Excellent Company, Lackluster StockNovember 6, 2024 | seekingalpha.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by International Assets Investment Management LLCInternational Assets Investment Management LLC increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 29,580.0% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,388 shares of the biopharmaceutical compaNovember 6, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comUltragenyx Pharmaceutical Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 5, 2024 | seekingalpha.comUltragenyx Reports Third Quarter 2024 Financial Results and Corporate UpdateNovember 5, 2024 | globenewswire.comWealth Enhancement Advisory Services LLC Purchases 14,394 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Wealth Enhancement Advisory Services LLC increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 195.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,753November 5, 2024 | marketbeat.comA Look Ahead: Ultragenyx Pharmaceutical's Earnings ForecastNovember 4, 2024 | benzinga.comEmerald Advisers LLC Has $31.65 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Emerald Advisers LLC increased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 17.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 569,798 shares of the biopharmaceutical company's stoNovember 3, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Position Trimmed by abrdn plcabrdn plc decreased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 11.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 253,304 shares of the biopharmaceutical company's stock after seNovember 2, 2024 | marketbeat.comWhat Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?November 1, 2024 | msn.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Pinnacle Associates Ltd.Pinnacle Associates Ltd. cut its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 25.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 119,360 shares of the biopharmaceutical company's stock after selling 4October 31, 2024 | marketbeat.comUltragenyx Pharmaceutical (RARE) to Release Quarterly Earnings on TuesdayUltragenyx Pharmaceutical (NASDAQ:RARE) will be releasing earnings after the market closes on Tuesday, November 5, Zacks reports.October 30, 2024 | marketbeat.comUltragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate UpdateOctober 30, 2024 | finance.yahoo.comRecent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 yearOctober 23, 2024 | finance.yahoo.comUltragenyx Pharmaceutical (RARE) Gets a Buy from Piper SandlerOctober 23, 2024 | markets.businessinsider.comUS FDA declines to approve Camurus' rare hormone disorder drugOctober 23, 2024 | reuters.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock, Insider Trading ActivityOctober 23, 2024 | benzinga.comUltragenyx Pharmaceutical's (RARE) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and issued a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday.October 22, 2024 | marketbeat.comUltragenyx price target raised to $73 from $61 at TD CowenOctober 21, 2024 | markets.businessinsider.comUltragenyx Pharmaceutical: Buy Rating Affirmed with Increased Price Target and Positive EPS OutlookOctober 21, 2024 | markets.businessinsider.comDecoding 10 Analyst Evaluations For Ultragenyx PharmaceuticalOctober 21, 2024 | benzinga.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 18, 2024 | globenewswire.comCwm LLC Purchases 21,111 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Cwm LLC grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9,552.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,332 shares of the biopharmaceutical company's stock after buying an additionOctober 17, 2024 | marketbeat.comJ.P. Morgan Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)October 14, 2024 | markets.businessinsider.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Sees Significant Decline in Short InterestUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) was the target of a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 2,890,000 shares, a decrease of 19.9% from the September 15th total of 3,610,000 shares. Based on an average daily volume of 705,100 shares, the days-to-cover ratio is presently 4.1 days.October 13, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn Sells 7,465 SharesOctober 12, 2024 | insidertrades.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Sells $393,853.40 in StockUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 7,465 shares of the business's stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at approximately $4,869,800.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.October 11, 2024 | marketbeat.com Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼0.480.55▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼146▲RARE Articles Average Week Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Perrigo News ACADIA Pharmaceuticals News Ionis Pharmaceuticals News Arrowhead Pharmaceuticals News Jazz Pharmaceuticals News Moderna News Viatris News Summit Therapeutics News Genmab A/S News Vaxcyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
